Declining incidence of invasive meningococcal disease in South Africa: 2003-2016.
Invasive meningococcal disease (IMD) is endemic to South Africa, where vaccine use is negligible. We describe the epidemiology of IMD in South Africa. IMD cases were identified through a national laboratory-based surveillance programme, GERMS-SA, from 2003-2016. Clinical data on outcome and HIV status were available from 26 sentinel hospital sites. We conducted space-time analysis to detect clusters of serogroup-specific IMD. Over 14 years, 5249 IMD cases were identified. Incidence was 0.97 cases per 100000 persons in 2003, peaked at 1.4 in 2006 and declined to 0.23 in 2016. Serogroup was confirmed in 3917 (75%) cases - serogroup A 5%, B 23%, C 9%, W 50%, Y 12%, X 0.3%, Z 0.1% and non-groupable 0.4%. Eight serogroup-specific geo-temporal clusters of disease were identified. Isolate susceptibility was 100% to ceftriaxone, 95% penicillin and 99.9% ciprofloxacin. In-hospital case-fatality was 17% (247/1479). Of those tested, 36% (337/947) were HIV-infected. IMD incidence in HIV-infected persons was higher for all age categories with age-adjusted relative risk ratio (aRRR) of 2.5 (95% CI 2.2-2.8, P<0.001) from 2012-2016. No patients reported previous meningococcal vaccine exposure. Patients with serogroup W were 3 times more likely to present with severe disease than those with serogroup B (aRRR 2.7 (95% CI 1.1-6.3)); HIV coinfection was twice as common with W and Y disease (aRRR W=1.8 (95% CI 1.1-2.9), Y=1.9 (95% CI 1.0-3.4)). In the absence of significant vaccine use, IMD in South Africa decreased by 76% from 2003-2016. HIV was associated with increased risk of IMD, especially serogroup W and Y disease.